NIH presents Chronocort® Phase 2 trial results

    RNS Number : 9022W
  Phoqus Pharmaceuticals PLC
  17 June 2008
   
    
    National Institutes of Health ("NIH") presents Chronocort® Phase 2 clinical trial results at ENDO in San Francisco

    West Malling, UK, 17 June 2008: Phoqus Pharmaceuticals plc (AIM: PQS) ("Phoqus" or the "Company"), the speciality pharmaceutical
company, announces that the results of the Phase 2 clinical trial of Chronocort ž004 were presented on 15 June by the NIH at the Endocrine
Society meeting in San Francisco.

    As announced by Phoqus on 3 March 2008, the conclusions from the study are that Chronocort® is safe and well tolerated in patients with
Congenital Adrenal Hyperplasia ("CAH"), with Chronocort® providing a more physiological cortisol profile than conventional therapy. A single
daily dose of Chronocort® given at 10pm provided a physiological night time and morning cortisol profile and control of morning levels of
the androgens ACTH and 17-OHP in patients with CAH. Whilst dose optimisation has not yet been studied, it is likely that giving the daily
dose of Chronocort® in two divided doses will improve androgen levels throughout the whole 24 hour period. A study to evaluate Chronocort®
given twice daily to patients with CAH is being planned with the NIH prior to initiation of a multi-centre trial.

    Phoqus Pharmaceuticals' CEO, Dr Richard Mason, commented:

    "These results give us great confidence that Chronocort is working as expected and that it will be a major step forward in the treatment
of Congenital Adrenal Hyperplasia and other forms of adrenal insufficiency including Addison's disease. Partnering discussions are
proceeding well with a number of speciality pharmaceutical and biotechnology companies."

    Enquiries:

    Phoqus Pharmaceuticals plc               Tel: [phone]
    Dr Richard Mason
    Dr Peter Johnson

    Nomura Code Securities Limited        Tel: [phone]
    Phil Walker 

    About Phoqus Pharmaceuticals

    Phoqus Pharmaceuticals is a speciality pharmaceutical company that aims to develop differentiated products for use in high value,
specialist indications. Its first product candidate is Chronocort®, a novel physiological cortisol replacement therapy in development for
the treatment of patients with congenital adrenal hyperplasia and Addison's disease. 

    Further background on the Company can be found at www.phoqus.com. 

This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
MSCEAFKXFFKPEFE